Shares of Dermata Therapeutics have moved -57.9% today, and are now trading at a price of $0.26. In contrast, the S&P 500 index saw a -1.4% change and the Dow Industrial Average posted a -1.3% performance. Today's trading volume is 4,822,440 compared to the stock's average volume of 192,996.
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. Based in San Diego, United States the company has 8 full time employees and a market cap of $3,117,526.
The company is now trading -96.57% away from its average analyst target price of $7.5 per share. The 2 analysts following the stock have set target prices ranging from $4 to $11, and on average give Dermata Therapeutics a rating of buy.
Over the last year, DRMA shares have gone down by -70.9%, which represents a difference of -59.5% when compared to the S&P 500. The stock's 52 week high is $2.73 per share and its 52 week low is $0.22. With its gross margins declining an average -0.0% over the last four years, Dermata Therapeutics may not have a strong enough business to reverse this trend.
